12 research outputs found
Stanowisko Komitetu Terapii i Nauk o Leku PAN (KTiNoL PAN), Komitetu Nauk Fizjologicznych i Farmakologicznych PAN (KNFiF), Polskiego Towarzystwa Farmakologicznego (PTF), Polskiego Towarzystwa Farmakologii Klinicznej i Terapii (PTFKiT), Polskiego Towarzystwa Nadci艣nienia T臋tniczego (PTNT) oraz Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego (SFSN PTK) dotycz膮ce chlorochiny w leczeniu zaka偶enia SARS-CoV-2 powoduj膮cego COVID-19
Stanowisko grupy ekspert贸w wsparte przez Sekcj臋 Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego dotycz膮ce miejsca standaryzowanej kompozycji polifenoli z bergamoty w terapii dyslipidemii oraz jej innego potencjalnego zastosowania
Bergamot juice has a particularly high content and a unique composition of flavonoids. It is particularly rich in flavanones and flavones. Standardized bergamot polyphenolic fraction has the same polyphenol profile as in the juice, but聽flavonoids are over 200 times more concentrated. Many data show its brilliant performance in hyperlipidaemia and聽moderate hyperglycaemia. In addition, it has other beneficial pleiotropic properties. The following document contains the聽opinion of an expert group summarizing current knowledge on bergamot flavonoids and their possible use in selected聽populations of patients.Sok bergamotowy charakteryzuje si臋 unikatowym profilem flawonoid贸w. Jest szczeg贸lnie bogaty we flawanony i flawony.聽Standaryzowana kompozycja polifenoli z bergamoty zawiera takie flawonoidy jak sok bergamotowy, jednak ponad聽200 razy bardziej skoncentrowane. Liczne dane wskazuj膮 na jej znakomite dzia艂anie w hiperlipidemii i umiarkowanej聽hiperglikemii. Ponadto wykazuje ona inne korzystne w艂a艣ciwo艣ci plejotropowe. Poni偶szy dokument stanowi opini臋 grupy聽ekspert贸w b臋d膮c膮 podsumowaniem aktualnej wiedzy na temat flawonoid贸w bergamoty i ich mo偶liwego zastosowania w wybranych populacjach chorych
Stanowisko grupy ekspert贸w wsparte przez Sekcj臋 Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego dotycz膮ce miejsca standaryzowanej kompozycji polifenoli z bergamoty w terapii dyslipidemii oraz jej innego potencjalnego zastosowania w praktyce klinicznej
Bergamot juice has a particularly high content and a unique composition of flavonoids. It is particularly rich in flavanones and flavones. Stan-dardized bergamot polyphenolic fraction has the same polyphenol profile as in the juice, but flavonoids are over 200 times more concentrated. Many data show its brilliant performance in hyperlipidaemia and moderate hyperglycaemia.
In addition, it has other beneficial pleiotropic properties. The following document contains the opinion of an expert group summarizing current knowledge on bergamot flavonoids and their possible use in selected populations of patients.Sok bergamotowy charakteryzuje si臋 unikatowym profilem flawonoid贸w. Jest szczeg贸lnie bogaty we flawanony i flawony. Standaryzowana kompozycja polifenoli z bergamoty zawiera takie flawonoidy jak sok bergamotowy, jednak ponad 200 razy bardziej skoncentrowane. Liczne dane wskazuj膮 na jej znakomite dzia艂anie w hiperlipidemii i umiarkowanej hiperglikemii. Ponadto wykazuje ona inne korzystne w艂a艣ciwo艣ci plejotropowe. Poni偶szy dokument stanowi opini臋 grupy ekspert贸w b臋d膮c膮 podsumowaniem aktualnej wiedzy na temat flawonoid贸w bergamoty i ich mo偶liwego zastosowania w wybranych populacjach chorych
Position paper of Scientific Committees of the Polish Academy of Sciences (Committee on Therapy and Drug Research, Committee on Physiology and Pharmacology) and Polish scientific societies (Polish Society of Pharmacology, Polish Society of Clinical Pharma
An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network
Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits
Vitamin D status determines the impact of metformin on circulating prolactin levels in premenopausal women
Sexual functioning and depressive symptoms in men with various types of prediabetes: a pilot study
Metabolic syndrome is associated with similar long-term prognosis in non-obese and obese patients. An analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 cohort studies
Aims We aimed to evaluate the association between metabolic syndrome (MetS) and long-term all-cause mortality. Methods The LIPIDOGRAM studies were carried out in the primary care in Poland in 2004, 2006 and 2015. MetS was diagnosed based on the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) and Joint Interim Statement (JIS) criteria. The cohort was divided into four groups: non-obese patients without MetS, obese patients without MetS, non-obese patients with MetS and obese patients with MetS. Differences in all-cause mortality was analyzed using Kaplan-Meier and Cox regression analyses. Results 45,615 participants were enrolled (mean age 56.3, standard deviation: 11.8 years; 61.7% female). MetS was diagnosed in 14,202 (31%) by NCEP/ATP III criteria, and 17,216 (37.7%) by JIS criteria. Follow-up was available for 44,620 (97.8%, median duration 15.3 years) patients. MetS was associated with increased mortality risk among the obese (hazard ratio, HR: 1.88 [95% CI, 1.79-1.99] and HR: 1.93 [95% CI 1.82-2.04], according to NCEP/ATP III and JIS criteria, respectively) and non-obese individuals (HR: 2.11 [95% CI 1.85-2.40] and 1.7 [95% CI, 1.56-1.85] according to NCEP/ATP III and JIS criteria respectively). Obese patients without MetS had a higher mortality risk than non-obese patients without MetS (HR: 1.16 [95% CI 1.10-1.23] and HR: 1.22 [95%CI 1.15-1.30], respectively in subgroups with NCEP/ATP III and JIS criteria applied). Conclusions MetS is associated with increased all-cause mortality risk in non-obese and obese patients. In patients without MetS obesity remains significantly associated with mortality. The concept of metabolically healthy obesity should be revised